Ventracor sees bright future despite losses
This article was originally published in Clinica
High expenditure on regulatory activities laid a significant dent in Ventracor's coffers, as the Australian developer of the VentrAssist left ventricle assist device recorded net loss of $36.5m for the year 2006/07. As it strives to expand its coverage in key international markets, the company said it spent heavily on guiding its lead technology through regulatory approvals in the US, Europe and Australia, but hopes to become profitable in the near future.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.